1153

500660

GLAXO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GLAXOSMITHKLINE PHARMA LT Share Price Today

GLAXOSMITHKLINE PHARMA LT is currently trading at ₹2121.5, up by ₹18.3 from the previous close. The stock touched an intraday high of ₹2131.90 and a low of ₹2088.10 during the latest trading session. Over the past one year, GLAXOSMITHKLINE PHARMA LT has delivered a loss of 37.73%, while the stock has declined 13.66% in the last one month.

GLAXOSMITHKLINE PHARMA LT performance

Today’s low Today’s high
₹ 2088.10 ₹ 2131.90
₹ 2121.50
52 week low 52 week high
₹ 2088.10 ₹ 3500.00
₹ 2121.50
Open Price ₹ 2116.00
Prev. Close ₹ 2103.20
Volume (Shares) 357494.00
Total traded value ₹ 7584.23
Upper Circuit ₹ 2523.80
Lower Circuit ₹ 1682.60
info

Investment Returns

Over 1 Month -13.66% Over 3 Months -15.39% Over 6 Months -19.78% Over 1 Year -37.73%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GLAXOSMITHKLINE PHARMA LT fundamentals


  • Market cap (Cr) 35,939.50
  • P/E Ratio (TTM) 35.50
  • Beta 0.68
  • Book Value / share 132.29
  • Return on equity 48.29%
  • EPS (TTM) 53.59
  • Dividend yield 2.69%
  • Net profit/quarter (Cr) 274.94
info icon alternate text
  • Market cap (Cr) 35,925.90
  • P/E Ratio (TTM) 35.50
  • Beta 0.65
  • Book Value / share 132.29
  • Return on equity 48.29%
  • EPS (TTM) 53.59
  • Dividend yield 2.69%
  • Net profit/quarter (Cr) 274.94
info icon alternate text

GLAXOSMITHKLINE PHARMA LT Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 989.15
Operating Expense 655.74
Net Profit 274.94
Net Profit Margin (%) 27.79
Earnings Per Share (EPS) 16.23
EBITDA 382.90
Effective Tax Rate (%) 25.51
Particulars DEC 2025 (Values in Cr)
Revenue 1022.59
Operating Expense 676.52
Net Profit 277.18
Net Profit Margin (%) 27.10
Earnings Per Share (EPS) 16.36
EBITDA 399.40
Effective Tax Rate (%) 26.65
Particulars SEP 2025 (Values in Cr)
Revenue 973.63
Operating Expense 656.89
Net Profit 255.00
Net Profit Margin (%) 26.19
Earnings Per Share (EPS) 14.92
EBITDA 368.59
Effective Tax Rate (%) 27.27
Particulars JUN 2025 (Values in Cr)
Revenue 804.83
Operating Expense 570.02
Net Profit 204.70
Net Profit Margin (%) 25.43
Earnings Per Share (EPS) 12.08
EBITDA 294.51
Effective Tax Rate (%) 26.51
Particulars MAR 2025 (Values in Cr)
Revenue 966.08
Operating Expense 650.64
Net Profit 260.14
Net Profit Margin (%) 26.92
Earnings Per Share (EPS) 15.35
EBITDA 370.20
Effective Tax Rate (%) 26.70
Particulars MAR 2026 (Values in Cr)
Revenue 3790.20
Operating Expense 2559.17
Net Profit 1011.82
Net Profit Margin (%) 26.69
Earnings Per Share (EPS) 59.59
EBITDA 1445.40
Effective Tax Rate (%) 26.47
Particulars MAR 2025 (Values in Cr)
Revenue 3723.49
Operating Expense 2622.29
Net Profit 919.06
Net Profit Margin (%) 24.68
Earnings Per Share (EPS) 54.01
EBITDA 1316.54
Effective Tax Rate (%) 26.38
Particulars MAR 2024 (Values in Cr)
Revenue 3407.25
Operating Expense 2578.08
Net Profit 584.69
Net Profit Margin (%) 17.16
Earnings Per Share (EPS) 40.83
EBITDA 880.52
Effective Tax Rate (%) 27.73
Particulars MAR 2023 (Values in Cr)
Revenue 3216.34
Operating Expense 2484.50
Net Profit 607.75
Net Profit Margin (%) 18.89
Earnings Per Share (EPS) 35.88
EBITDA 899.95
Effective Tax Rate (%) 27.35
Particulars MAR 2022 (Values in Cr)
Revenue 3217.51
Operating Expense 2531.85
Net Profit 1690.53
Net Profit Margin (%) 52.54
Earnings Per Share (EPS) 99.79
EBITDA 843.63
Effective Tax Rate (%) 51.31
Particulars MAR 2026 (Values in Cr)
Book Value / Share 133.85
ROE % 49.11
ROCE % 59.05
Total Debt to Total Equity 0.01
EBITDA Margin 38.60
Particulars MAR 2025 (Values in Cr)
Book Value / Share 115.19
ROE % 49.75
ROCE % 59.29
Total Debt to Total Equity 0.01
EBITDA Margin 35.42
Particulars MAR 2024 (Values in Cr)
Book Value / Share 104.93
ROE % 37.32
ROCE % 44.97
Total Debt to Total Equity 0.01
EBITDA Margin 28.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 102.79
ROE % 27.73
ROCE % 33.92
Total Debt to Total Equity 0.01
EBITDA Margin 27.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 157.19
ROE % 81.31
ROCE % 32.55
Total Debt to Total Equity 0.01
EBITDA Margin 25.53
Particulars MAR 2026 (Values in Cr)
Book Value / Share 132.30
ROE % 48.29
ROCE % 58.17
Total Debt to Total Equity 0.01
EBITDA Margin 38.14
Particulars MAR 2025 (Values in Cr)
Book Value / Share 115.06
ROE % 49.23
ROCE % 58.72
Total Debt to Total Equity 0.01
EBITDA Margin 35.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 105.31
ROE % 36.83
ROCE % 44.44
Total Debt to Total Equity 0.01
EBITDA Margin 28.60
Particulars MAR 2023 (Values in Cr)
Book Value / Share 103.48
ROE % 27.43
ROCE % 33.60
Total Debt to Total Equity 0.01
EBITDA Margin 28.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 158.06
ROE % 80.45
ROCE % 32.11
Total Debt to Total Equity 0.01
EBITDA Margin 25.83
Particulars MAR 2026 (Values in Cr)
Cash & Short Term Investments 1391.01
Total Assets 4323.86
Total Liabilities 4323.86
Total Equity 2267.41
Share Outstanding 16
Price to Book Ratio 17.26
Return on Assets (%) 23.95
Return on Capital (%) 45.69
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1403.51
Total Assets 4108.06
Total Liabilities 4108.06
Total Equity 1951.31
Share Outstanding 16
Price to Book Ratio 25.01
Return on Assets (%) 22.57
Return on Capital (%) 47.54
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1063.21
Total Assets 3556.61
Total Liabilities 3556.61
Total Equity 1777.63
Share Outstanding 16
Price to Book Ratio 18.45
Return on Assets (%) 16.58
Return on Capital (%) 33.19
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1155.92
Total Assets 3326.58
Total Liabilities 3326.58
Total Equity 1741.27
Share Outstanding 16
Price to Book Ratio 12.80
Return on Assets (%) 18.35
Return on Capital (%) 35.07
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2484.50
Total Assets 4633.27
Total Liabilities 4633.27
Total Equity 2662.95
Share Outstanding 16
Price to Book Ratio 10.52
Return on Assets (%) 36.57
Return on Capital (%) 63.64
Particulars MAR 2026 (Values in Cr)
Cash & Short Term Investments 1354.79
Total Assets 4274.91
Total Liabilities 4274.91
Total Equity 2241.17
Share Outstanding 16
Price to Book Ratio 17.26
Return on Assets (%) 23.66
Return on Capital (%) 45.15
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1400.88
Total Assets 4100.93
Total Liabilities 4100.93
Total Equity 1949.23
Share Outstanding 16
Price to Book Ratio 25.01
Return on Assets (%) 22.41
Return on Capital (%) 47.15
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1061.19
Total Assets 3547.80
Total Liabilities 3547.80
Total Equity 1784.09
Share Outstanding 16
Price to Book Ratio 18.45
Return on Assets (%) 16.48
Return on Capital (%) 32.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1150.73
Total Assets 3327.69
Total Liabilities 3327.69
Total Equity 1752.99
Share Outstanding 16
Price to Book Ratio 12.80
Return on Assets (%) 18.26
Return on Capital (%) 34.67
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2479.11
Total Assets 4622.59
Total Liabilities 4622.59
Total Equity 2677.61
Share Outstanding 16
Price to Book Ratio 10.52
Return on Assets (%) 36.57
Return on Capital (%) 63.14
Particulars MAR 2026 (Values in Cr)
Net Income 1385.38
Cash from Operations 1221.97
Cash from Investing 396.98
Cash from Financing -737.07
Net change in Cash 563.20
Free Cash Flow 1277.25
Particulars MAR 2025 (Values in Cr)
Net Income 1255.18
Cash from Operations 1371.60
Cash from Investing -45.80
Cash from Financing -769.42
Net change in Cash 474.67
Free Cash Flow 1394.62
Particulars MAR 2024 (Values in Cr)
Net Income 959.80
Cash from Operations 975.69
Cash from Investing 8.71
Cash from Financing -561.49
Net change in Cash 29.23
Free Cash Flow 1006.91
Particulars MAR 2023 (Values in Cr)
Net Income 841.49
Cash from Operations 755.74
Cash from Investing 807.85
Cash from Financing -1543.32
Net change in Cash -251.24
Free Cash Flow 799.78
Particulars MAR 2022 (Values in Cr)
Net Income 2475.64
Cash from Operations 959.03
Cash from Investing -405.50
Cash from Financing -524.24
Net change in Cash -119.00
Free Cash Flow 993.67
Particulars MAR 2026 (Values in Cr)
Net Income 1373.58
Cash from Operations 1201.52
Cash from Investing 385.25
Cash from Financing -737.07
Net change in Cash 529.60
Free Cash Flow 1256.80
Particulars MAR 2025 (Values in Cr)
Net Income 1243.74
Cash from Operations 1360.95
Cash from Investing -36.53
Cash from Financing -769.42
Net change in Cash 474.07
Free Cash Flow 1383.97
Particulars MAR 2024 (Values in Cr)
Net Income 952.65
Cash from Operations 971.05
Cash from Investing 14.96
Cash from Financing -561.49
Net change in Cash 32.40
Free Cash Flow 1002.27
Particulars MAR 2023 (Values in Cr)
Net Income 837.48
Cash from Operations 757.61
Cash from Investing 805.19
Cash from Financing -1544.17
Net change in Cash -251.04
Free Cash Flow 801.65
Particulars MAR 2022 (Values in Cr)
Net Income 2470.04
Cash from Operations 968.00
Cash from Investing -419.66
Cash from Financing -524.24
Net change in Cash -124.11
Free Cash Flow 1002.64
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.52 13.02 1.52 241.55 23.12 38.85
BLISS GVS PHARMA LTD. 436.05 35.28 3.86 4612.93 118.35 462.70
CIPLA LTD 1383.00 29.35 3.24 111725.01 1165.55 1672.20
FERMENTA BIOTECH LTD. 328.55 14.49 2.37 966.96 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.52 22.04 4.06 241.55 23.12 38.85
AMRUTAJAN HEALTH LTD 562.65 25.22 4.39 1626.66 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8248.80 107.73 23.62 20622.00 7630.00 10653.05
BLISS GVS PHARMA LTD. 436.05 46.89 3.99 4612.93 118.35 462.70

GLAXOSMITHKLINE PHARMA LT shareholding pattern

Holding
12.69%
75.0%
4.62%
7.68%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

GLAXOSMITHKLINE PHARMA LT Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2121.50 0.87 redarrow
red-green-graph indicator
9 Bearish
7 Bullish
  • 5 Days 2145.70
  • 26 Days 2255.60
  • 10 Days 2176.40
  • 50 Days 2317.70
  • 12 Days 2188.70
  • 100 Days 2394.40
  • 20 Days 2231.50
  • 200 Days 2495.90
2123.07 PIVOT
First Support 2076.13 First Resistance 2150.13 Second Support 2049.07 Second Resistance 2197.07 Third Support 2002.13 Third Resistance 2224.13
RSI 24.22 ADX 30.72 MACD -65.44 Williams % R -97.10 Commodity Channel Index (CCI) -110.29
Date 2026-06-11 Week 56133.00 Same Day 168414.00 Month 62866.00
1 Year 0.69 3 Year 0.65
Over 1 Month
-13.66% down
Over 1 Year
-37.73% down
Over 3 Months
-15.39% down
Over 3 Years
14.87% down
Over 6 Months
-19.78% down
Over 5 Years
6.75% down

GLAXOSMITHKLINE PHARMA LT Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
29 May 2026 57.0 Final 29 May 2026 Equity shares
30 May 2025 42.0 Final 30 May 2025 Equity shares
07 Nov 2024 12.0 Special 07 Nov 2024 Equity shares
31 May 2024 32.0 Final 31 May 2024 Equity shares
30 Jun 2023 32.0 Final 30 Jun 2023 Equity shares
07 Jul 2022 60.0 Special 08 Jul 2022 Equity shares
07 Jul 2022 30.0 Final 08 Jul 2022 Equity shares
19 Jul 2021 30.0 Final 20 Jul 2021 Equity shares
17 Jul 2020 20.0 Special 20 Jul 2020 Equity shares
17 Jul 2020 20.0 Final 20 Jul 2020 Equity shares
11 Jul 2019 20.0 Final 15 Jul 2019 Equity shares
13 Jul 2018 35.0 Final 17 Jul 2018 Equity shares
14 Jul 2017 30.0 Final 18 Jul 2017 Equity shares
15 Jul 2016 50.0 Final 19 Jul 2016 Equity shares
23 Jul 2015 62.5 Final 25 Jul 2015 Equity shares
03 Apr 2014 50.0 Final 07 Apr 2014 Equity shares
04 Apr 2013 50.0 Final 08 Apr 2013 Equity shares
29 Mar 2012 45.0 Final 02 Apr 2012 Equity shares
14 Mar 2011 40.0 Final 16 Mar 2011 Equity shares
10 Mar 2010 30.0 Final 12 Mar 2010 Equity shares
18 Mar 2009 18.0 Special 20 Mar 2009 Equity shares
18 Mar 2009 22.0 Final 20 Mar 2009 Equity shares
02 Apr 2008 18.0 Special 04 Apr 2008 Equity shares
02 Apr 2008 18.0 Final 04 Apr 2008 Equity shares
14 Mar 2007 14.0 Special 16 Mar 2007 Equity shares
14 Mar 2007 17.0 Final 16 Mar 2007 Equity shares
Ex-Date Ex-Bonus Ratio
13 Sep 2018 11 Sep 2018 1:1
Dividend date Dividend amount Dividend type Record date Instrument type
29 May 2026 57.0 Final 29 May 2026 Equity shares
30 May 2025 42.0 Final 30 May 2025 Equity shares
07 Nov 2024 12.0 Special 07 Nov 2024 Equity shares
31 May 2024 32.0 Final 31 May 2024 Equity shares
30 Jun 2023 32.0 Final 30 Jun 2023 Equity shares
07 Jul 2022 60.0 Special 08 Jul 2022 Equity shares
07 Jul 2022 30.0 Final 08 Jul 2022 Equity shares
19 Jul 2021 30.0 Final 20 Jul 2021 Equity shares
17 Jul 2020 20.0 Special 20 Jul 2020 Equity shares
17 Jul 2020 20.0 Final 20 Jul 2020 Equity shares
11 Jul 2019 20.0 Final 15 Jul 2019 Equity shares
13 Jul 2018 35.0 Final 17 Jul 2018 Equity shares
14 Jul 2017 30.0 Final 18 Jul 2017 Equity shares
15 Jul 2016 50.0 Final 19 Jul 2016 Equity shares
23 Jul 2015 62.5 Final 25 Jul 2015 Equity shares
03 Apr 2014 50.0 Final 07 Apr 2014 Equity shares
04 Apr 2013 50.0 Final 08 Apr 2013 Equity shares
29 Mar 2012 45.0 Final 02 Apr 2012 Equity shares
14 Mar 2011 40.0 Final 16 Mar 2011 Equity shares
10 Mar 2010 30.0 Final 12 Mar 2010 Equity shares
18 Mar 2009 18.0 Special 20 Mar 2009 Equity shares
18 Mar 2009 22.0 Final 20 Mar 2009 Equity shares
02 Apr 2008 18.0 Special 04 Apr 2008 Equity shares
02 Apr 2008 18.0 Final 04 Apr 2008 Equity shares
14 Mar 2007 14.0 Special 16 Mar 2007 Equity shares
14 Mar 2007 17.0 Final 16 Mar 2007 Equity shares
Ex-Date Ex-Bonus Ratio
13 Sep 2018 11 Sep 2018 1:1

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

Glaxosmithkline Pharmaceuticals Ltd share price is for NSE ₹ 2,121.50 & for BSE ₹ 2,115.70 as on Jun 12 2026 03:30 PM.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glaxosmithkline Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 12 2026 03:30 PM.

What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd for NSE is ₹ 3,500.00 and ₹ 2,088.10 and for BSE is ₹ 3,500.00 and ₹ 2,088.00.

What is 1 year return for Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -36.09%.

What is the P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM the price-to-earnings (PE) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 35.50.

What is the PB ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM, the price-to-book (PB) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 132.29.

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glaxosmithkline Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glaxosmithkline Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glaxosmithkline Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|